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The comparison of fitness between cells leads to the elimination of less compe-
tent cells in the presence of more competent neighbors via cell competition (CC).
This phenomenon has been linked with several cancer-related genes and thus
may play an important role in cancer. Various processes are involved in the
regulation of tumor initiation and growth, including tumor hypoxia, clonal stem
cell selection, and immune cell response, all of which have been recently
shown to have a potential connection with the mechanisms involved in CC.
This review aims to unravel the relation between these processes and competi-
tive cell interactions and how this affects disease progression.
CC, Associated Processes, and Cancer
CC is a process by which measurements of relative fitness in neighboring cells allow communities
to eliminate defective or damaged cells (called ‘losers’) to favor the proliferation and growth of
competent cells (‘winners’) [1,2]. Several CC mechanisms exist, notably the comparison of
‘fitness fingerprints’ [3]. These aid in maintaining homeostasis, and defects in CC mechanisms
are implicated in ageing and carcinogenesis [4,5]. Numerous processes influence carcinogenesis:
(i) hypoxia promotes aggressiveness and resistance to therapy [6,7]; (ii) clonal selection of
stem cells contributes to tumor development and heterogeneity [8,9]; and (iii) immune cell
responses select and affect the outcome of cancer and cancer cells [10,11]. Tumor cells start
growing in a hostile environment and depend on CC mechanisms to acquire a competitive state,
which allows them to overcome the continuous repression of neighbor cells [12,13]. This seems
to be conserved in mammals [3].
Flower-Based CC and Its Role in Cancer
In humans, C9ORF7 encodes for four splicing variants of the transmembrane protein Flower
(hFWE1–4) [3]. Recent data showed that cells expressing hFWE isoforms under monoculture
conditions are not eliminated by apoptosis. However, co-culture studies revealed that cells
expressing hFWE2 or hFWE4 proliferate and trigger caspase-dependent apoptosis of cells
expressing hFWE1 or hFWE3 [3]. Thus, hFWE2 and hFWE4 are considered hFWEWin isoforms,
whereas hFWE1 and hFWE3 are considered hFWELose isoforms. These data suggested that
Flower isoforms act as fitness fingerprints in CC events based on the comparison of the isoforms
expressed by cells [3].
Analyses of human tumor samples revealed that tumor cells express predominantly hFWEWin iso-
forms, whereas the adjacent stromal cells express hFWELose. In normal tissue, all hFWE isoforms
are poorly expressed [3]. Further analyses of the tumor microenvironment (TME) showed that the
expression of hFWELose isoforms as well as the expression of genes involved in apoptosis
increases as stromal tissue approach the edge of tumor tissue [3]. Overall, these data suggested
that tumors can outcompete their adjacent cells through Flower-mediated CC.
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Further work in mice showed that tumor cells overexpressing human FweWin form larger tumors
and develop more metastases in mice with a FweLose background than in mice with a FweKO
background [3]. Additionally, the expression of FweLose increases in FweWT mice harboring
FweWin tumors. Therefore, the interaction between the tumor and the TME may contribute to
tumor progression, as FweWin tumors promote the non-autonomous expression of FweLose
in stromal tissue [3].
The expression levels of hFWEWin influence the tumorigenic potential of cells, as metastatic cells
with higher expression of hFWEWin develop larger tumors than cells with lower expression of
hFWEWin [3]. Moreover, the tumorigenic potential of cells expressing hFWEWin decreased on its
knockdown (KD), as these cells formed smaller tumors with less metastatic potential [3]. These
findings were further enhanced when hFWEWin KDwas combined with chemotherapy, suggesting
that combining hFWE target therapy with standard-of-care therapy could decrease tumorigenicity
by impairing growth and metastatic potential in tumors [3].
Multiple CC Pathways in Regulation of Cancer
Tissue homeostasis is under a strict balance between proliferation of competent cells and elimi-
nation of cells harboring defects, such as mutations that could result in cancer development
[14,15]. To maintain this balance, cells use defense mechanisms that allow them to identify and
eliminate these defective cells. One of such mechanisms is the epithelial defense against cancer
(EDAC), which results in the apical extrusion (see Glossary) of potentially oncogenic cells from
the epithelial layer [14]. EDAC is a CCmechanism in which normal cells surround and eliminate, in
a nonautonomous fashion, cells expressing oncoproteins such as RasV12, Erb, Src, or constitu-
tively active forms of Cdc42 [14]. The surrounding normal cells influence cytoskeletal rearrange-
ments that result in the accumulation of cytoskeletal proteins at the boundary, generating
contractile forces and metabolic changes on transformed cells, which facilitates their apical
elimination from the epithelial layer [14].
Cells harboring mutations bypass tissue surveillance systems such as EDAC, hijack CC mecha-
nisms, and eliminate normal cells causing diseases such as cancer [14]. One of the most-studied
proteins associated with CC events, which is known to develop the supercompetitor phenotype,
is MYC [16]. MYC is frequently upregulated in many cancers and drives tumorigenesis by induc-
ing metabolic shift and promoting cell growth and proliferation [17]. In human cancers, the over-
expression ofMYC in tumor cells causes the nonautonomous apoptosis of adjacent stromal cells
by activation of the caspase pathway [18]. CC assays inDrosophila and in human cancer cell lines
have shown that cells can sense different expression and activation levels of MYC as a fitness
marker. When cells with different levels of MYC are cultured separately, their proliferation and
apoptotic rates are similar [17]. However, when these cells are co-cultured, those with higher
levels of MYC have increased proliferation rates and induce the elimination by apoptosis through
caspase activation of those expressing lower levels of this protein [17,18].
Intriguingly, MYC-mediated CC mechanisms have been found to be regulated by the Hippo
pathway, as a consequence of the loss of cell polarity. This has been observed in Drosophila
and humans [18]. Deregulation of HUGL-1 (homolog of Drosophila lgl) causes loss of polarity
and promotes the nuclear translocation of YAP (homolog ofDrosophila Yki), leading toMYC over-
expression [18]. YAP is highly expressed in various cancer types and its activation can further
facilitate tumorigenesis by promoting cell proliferation, migration, survival, and chemoresistance
[19,20] and by modulating the immune system [19]. Recently, a study using glioma cells in
mouse models demonstrated that differential YAP expression in tumor cells triggers competition
events thus contributing to tumor progression [19]. In co-culture conditions, cells expressing
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higher levels of YAP have enhanced growth and cause the elimination by apoptosis of cells
expressing lower levels of this protein [19]. Moreover, RNA-seq data from cells expressing higher
and lower YAP levels cultured in a homogeneous or heterogeneous environment showed that a
set of tumorigenesis-related genes is induced in cells on competition [19].
Mutations in TP53 are commonly found in cancer cells and may result in abrogation of p53 tumor
suppressive functions, such as cell-cycle arrest and apoptosis [21]. This allows the accumulation
of oncogenic mutations and favors resistance to genomic instability and other stress conditions,
such as starvation and hypoxia [21]. Several studies have revealed the roles of p53 in CC [22,23].
As an example, increased p53 levels in Bmpr1a−/- cells inhibit mTOR signaling and decrease their
metabolic activity, thus causing their elimination by apoptosis when co-cultured with wild-type
(WT) cells [22]. Additionally, mechanical compression can induce p53 elevation in less-fit cells
and cause their elimination by apoptosis [23]. Furthermore, p53 expression is higher in Myc
supercompetent cells and is required to enhance metabolic reprograming and sustain cell pro-
liferation [24]. Thus, the accumulation of mutant forms of p53 in cancer cells could simultaneously
confer resistance to apoptosis and support cancer cell proliferation through Myc activity.
In this review, we prepare a revised summary of CC genes that are
involved in the regulation of cancer, in human and mouse models
(Table 1) [3,5,17,22,23,25–42].
Hypoxia and Its Influence on Cancer
Hypoxia is characterized by deficient oxygen levels leading to cellular
changes largely driven by hypoxia inducible factor (HIF) signaling [43].
HIFs are a family of transcription factors – HIF-1, HIF-2, and HIF-3 –
comprising an alpha subunit that is stabilized on hypoxia and a consti-
tutively expressed β-subunit (ARNT) [6]. HIFs induce changes in the
cellular transcriptome controlling metabolism, glucose uptake, pro-
liferation, differentiation, and survival as well as angiogenesis and
erythropoiesis [6]. Although it has been demonstrated that HIF-1α
may play opposite roles in tumor progression [44], studies show
that, in a hypoxic microenvironment, activated HIF-1α may promote
epithelial-to-mesenchymal transition (EMT), which in turn pro-
motes invasion, a cancer stem cell (CSC)-like phenotype, and resis-
tance to chemotherapy [6]. HIF-1α can also promote cancer migration
by regulating the expression of enzymes that polymerize thus regulate
the alignment of collagen fibers and the activity of integrins [45]. Last,
hypoxia promotes endothelial cell contraction, which makes vessels
leaky and aids the passage of metastatic cancer cells through blood
and lymphatic vessels [46]. It has been observed that the HIF-1α protein
is overexpressed in several solid malignancies, including breast, colon,
gastric, lung, skin, ovarian, pancreatic, and prostate, compared with
their respective normal tissues [6]. Furthermore, in response to hypoxia
HIF-1 can activate the multidrug resistance 1 (MDR1) gene, thus pro-
moting chemoresistance [45]. Taking these findings together, hypoxia
promotes tumor growth and metastasis (Figure 1A).
Hypoxia Regulates the Expression of CC Genes
Some CC genes in Table 1 have been shown to play a role
in oncogenesis, cancer growth, or metastasis and to exhibit
Glossary
Apical extrusion: a CC mechanism by
which transformed cells are eliminated
from the epithelia, allowing ‘loser’ cells to
be eliminated while ‘winner’ cells
proliferate [78].
Epithelial-to-mesenchymal
transition (EMT): a phenomenon
through which epithelial cells lose their
polarity and acquire migratory potential,
thus promoting metastasis formation.
The mechanisms involve the regulation
of proteins such as E-cadherin and
increase of mesenchymal markers [79].
Table 1. List of Genes In-
volved in CC Mechanisms
That Play Important Roles
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differences in their expression profiles under hypoxic conditions, thus contributing to tumor
aggressiveness.
Some studies have uncovered a relationship between hypoxia and the Wnt/β-catenin pathway
[47–49]. A study found that WNT11, which is highly expressed in several cancers and implicated
in proliferation, migration, and invasion, is induced by hypoxia in various cell types [47]. Under
hypoxic conditions, HIF-1α augments WNT11 expression, thus promoting the migration and
invasion of tumor cells through the activation of matrix metalloproteinase (MMP)-2 and MMP-9
[47]. Additionally, in vivo experiments showed that WNT11 is mainly expressed in hypoxic
areas and its KD reduces tumor growth in mice, which suggests that WNT11 may increase the
metastatic potential of tumor cells under hypoxia [47].
Bone morphogenetic proteins (BMPs) have been previously associated with CC. In mammals, plu-
ripotent cells with decreased BMP signaling are eliminated in the presence ofWT cells [22]. Several
studies have connected increases in BMP levels with patient outcomes in many cancers, including
hepatocellular carcinoma (HCC) [50]. It was shown that hypoxia induces BMP4 expression in HCC
cells and that two Ets-1-binding-sites in the BMP4 promoter have increased activity under hypoxic
conditions [50]. Further, transfection of the dominant-negative HIF-1α isoform abrogates BMP4
expression [50]. This hypoxia-regulated expression of BMP4 supports the idea that CC genes
may play a role in the increased tumor aggressiveness caused by hypoxia.
A study demonstrated that hypoxia can activate YAP by promoting its nuclear localization in HCC
cells [20]. Under this condition, YAP binds to HIF-1α in the HCC cell nucleus, thus sustaining
HIF-1α stabilization, which promotes cell glycolysis. Moreover, it was shown that silencing
YAP inhibits HCC cell glycolysis in hypoxic conditions and reduces their invasion and migration
[20]. This example suggests that YAP is involved in promoting cancer cell glycolysis in hypoxia
thereby contributing to tumor cells’ aggressiveness.
HIF-1α and HIF-2α demonstrate disparate roles in their regulation of c-Myc expression and func-
tion, dependent not on the level of hypoxia but instead on its duration [51]. Acute hypoxia (2 h)
upregulated c-Myc mRNA and protein expression via HIF-1α activity, driving chemoresistance
of colorectal cancer cells and thus enhancing tumor aggressiveness. By contrast, HIF-2α con-
trolled c-Myc expression during chronic hypoxia (over 8 h), leading to chemosensitivity [51].
HIF-1α upregulates p53 expression by binding to HIF-1α response elements (HREs) and inter-
acts with p53, despite its mutational status, to form a HIF-1α–p53 complex [6]. In this complex,
p53 adopts a mutant-like conformation, which indicates that, under hypoxic conditions, cells
adopt a phenotype reminiscent of a mutant p53 genotype regardless of whether they harbor a
mutation in TP53. Notably, hypoxia also selects for apoptosis-resistant cells [52]. Taking these
findings together, hypoxic cells can outcompete normoxic WT TP53 cells through CC, and this
p53-dependent mechanism then promotes cancer aggressiveness (Figure 1B). Thus, we
Figure 1. Cell Competition-Dependent Mechanisms That Promote Cancer Aggressiveness. (A) Representation of a tumor region where tumor cell proliferation
and/or vessel dysfunction has created a site of hypoxia distal from accessible oxygen diffusion. Other tumor regions remain with normal oxygen levels (normoxia). Hypoxia
activates pathways in some hypoxic cells that generate a fitness winner phenotype, while neighboring cells in the hypoxic region display a fitness loser phenotype and
undergo apoptosis. (B) Cell competition selects for hypoxic cells and MUT p53 cells. Under hypoxic conditions, p53 complexes with hypoxia inducible factor 1 alpha
(HIF-1α) and acquires a mutant-like conformation independent of its genetic sequence. Hypoxic cells and cells harboring a p53 mutation (MUT p53) outcompete their
normoxic wild-type (WT) counterparts, leading to neoplastic growth. (C) Human high-grade serous ovarian carcinoma sample stained with hematoxylin and eosin (H&E)
(left) and with anti-HIF-1α (right). The image shows hypoxic tumor regions with predominant HIF-1α stabilization (nuclear staining; orange arrowheads) and normoxic
tumor regions (blue arrowheads). Hypoxia has been reported to trigger cell fitness pathways including MYC, WNT, DPP, JAK, Hippo, and Scribble and their
downstream effectors JNK, p53, Azot, NF-kB, and Sparc.
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propose a model to depict the relationship between hypoxic and normoxic zones in cancer and
the role of CC genes and HIF signaling (Figure 1C). To further support our model, we performed a
secondary analysis of publicly available RNA-seq data to highlight the relationship between CC
gene expression and hypoxia (Box 1).
Role of CC in Selection of Therapy-Resistant Stem Cell Populations
Stem cells exist in niches adapted for their growth and that provide signals for their maintenance [53].
Therefore, stem cells compete continuously with their neighbors for niche occupancy [54]. CC can
function as a tumor suppressor system, by eradicating, as an example, cells with apicobasal polarity
mutations from stem cell niches [4]. However, stem cells with malignant propensities can also use
CCmechanisms to outcompete normal stemcells and colonize these niches [4]. Stemcell populations
are maintained by asymmetric divisions and can be lost or replaced stochastically to maintain homeo-
stasis, in a process termed neutral competition [54,55]. Another type of stem CC, termed non-neutral
competition, occurs between two unequal stem cell populations. The development of mutations in a
fraction of stem cells in a niche can lead to the selection/elimination of stem cells that have a
competitive advantage/disadvantage over their non-mutant neighbors [54]. Non-neutral com-
petition can arise in CSCs as a response to different therapies. With mutations that help CSCs
evade various therapies, the population becomes enriched with resistant mutant CSCs due to
selective pressure.
The clonal evolution (CE) model and the CSCmodel are two independent models of cancer devel-
opment, but recent studies highlight the intersections between thesemodels [8,56]. The CEmodel
states that cancer development is an evolutionary process, with the accumulation of genetic and
epigenetic alterations resulting in complex heterogeneity [57]. The CSC model hypothesizes that
cancers are initiated through initiator cells and states that cancers emerge from a restricted fraction
of CSCs [58]. Some investigators believe these two models are complementary and should be
combined as they highlight different aspects of the same cancer [8,59], and it has been shown
that CE occurs in CSCs [8] and that CSCs can thus represent a heterogeneous target, with multiple
subpopulations with various therapy sensitivities coexisting, competing, and evolving in the same
tumor (Figure 2A). Further accumulation of mutations in CSCs will result in differentially behav-
ing populations. A new mutation could lead to the acquisition of migratory ability, thereby
separating ‘stationary CSCs’ from ‘migrating CSCs’, which can form metastases [8]. This het-
erogeneity and CE contribute to CSC competition leading to the complexities of cancer
detection, targeting, and prognosis. The instructive value of the CSC model relies on two pre-
mises: first, not all cancer cells are CSCs; and second, CSCs can be distinguished from non-
CSCs and CC favors the survival of CSCs. Consequently, CSCs can survive stressful conditions
such as the presence of chemotherapeutic agents, hypoxia [60], or radiotherapy [61].
CC Pathways Mediate the Relation between Cancer and Immune Cells
The immune system is balanced between pro- and anti-inflammatory states and a one-way
deviation can lead to autoimmunity or cancer, respectively [62]. This balance requires constant replen-
ishment and trophic support for various cell subsets to prevent pathology. For example, depletion of
regulatory T cells (Tregs) abrogates peripheral tolerance and promotes autoimmunity [63]. The way in
which CC regulates interactions between immune cells is not well understood. From the bone mar-
row to peripheral tissues, immune cells must respond to various environmental cues to function
and mature properly. The tissue microenvironment significantly affects competition by providing
different factors. One study highlights the importance of CC in the maintenance of immune function
and development to prevent incipient immune cell neoplasia by subjecting immune cell populations
to competitive pressures in the thymus [64]. Additionally, pathological niches such as TME have a
unique set of rules that influence the interaction between immune cells.
Trends in Cell Biology
972 Trends in Cell Biology, December 2020, Vol. 30, No. 12
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on December 16, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
CC in the Bone Marrow: A Tumor Suppressor Mechanism for Hematological
Cancers
Immune cell precursors develop from hematopoietic stem cells (HSCs) replenished by the bone
marrow. Studies in HSCs have shown that p53 mediates CC in a manner independent of its
DNA-damage response [31,65], as relative (not absolute) levels of p53 lead to growth arrest by
Box 1. CC-Dependent Mechanisms That Promote Cancer Aggressiveness
We have proposed a model depicting the relationship between hypoxic zones of cancer, CC, and the role of CC genes in manifesting HIF-regulated signaling, eventually
promoting cancer growth and aggressiveness (Figure 1C in the main text). To identify the relation between the genes that control CC mechanisms (Table 1) and hypoxia
in solid tumors, we performed a secondary analysis of CC genes from HCT-116 cultured under hypoxia and normoxia (Figure IA). The results show that many CC genes
are differentially expressed under hypoxic conditions compared with normoxic (Figure IA,B). Using a combined list of the top-200 upregulated genes on hypoxia and our
list of CC genes, we performed gene/protein co-occurrence/interaction mapping using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING)
database (https://string-db.org). STRING analysis shows significant correlations between CC genes and genes that are upregulated under hypoxia (Figure IC).
Trends in Cell Biology
Figure I. RNA-Seq Reveals Differential
Expression of Cell Competition (CC) Genes
Enriched under Hypoxic Conditions.
(A) Heatmap of the expression of CC genes (Table 1)
from publicly available RNA-seq data (GSE101526).
Expression of CC genes was analyzed in HCT-116
cultured under hypoxia or normoxia. The FPKM
values were used to calculate differential expression
of genes. The heatmap shows averaged expression
of theCCgenes in thegroupsusing z-scorenormaliza-
tion. Differential expression analysis of CC genes was
conducted using DESeq2. (B) Bar plot of ten CC
genes from the heatmap that were significantly differ-
entially expressed (P b 0.05, Student’s two-sided t-
test). (C) Using a combined list of the top-200 upregu-
lated genes on hypoxia and our list of CC genes, we
performed gene/protein co-occurrence/interaction
mapping using the Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) database
(https://string-db.org). We used only the correlations
between genes from ‘experiments’ and ‘databases’
gene interaction catalogs of the STRING software.
With those, we excluded random interactions, caused
by co-occurrence in the paper texts, as well as other
forms of data mining, and kept only the genes for
which interactions were properly filed. We utilized the
highest stringency (0.9) on correlation analysis instead
of the default medium stringency (0.4). The genes/pro-
teins related to the GO term ‘(GO:0001666) Re-
sponse to hypoxia’ are marked with blue. The
genes/proteins associated with the KEGG term
‘hsa05200 Pathways in cancer’ are marked in
red. Both terms were significantly enriched in the
input set of genes (FDR = 1.66e-14 and FDR =
1.16e-15, respectively), which excludes their appear-
ance as a random event. Data analysis and visualiza-
tions were performed in R, using DESeq2, gplots,
viridis, RColorBrewer, dplyr, ggplot2, readr, plyr,
tidyr, readxl, ggrepel, EnsDb.Hsapiens.v86, and
ggridges.
Trends in Cell Biology
Trends in Cell Biology, December 2020, Vol. 30, No. 12 973
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on December 16, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
Trends in Cell Biology
(See figure legend at the bottom of the next page.)
Trends in Cell Biology
974 Trends in Cell Biology, December 2020, Vol. 30, No. 12
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on December 16, 2020.
For personal use only. No other uses without permission. Copyright ©2020. Elsevier Inc. All rights reserved.
neighbors with lower p53 levels rather than apoptosis. This mechanism minimizes the risk of
development of hematological neoplasia by permitting clonal expansion of HSCs with low p53
levels and, presumably, low mutational burden or stressful insult.
Mutations in p53 can cause myelodysplastic syndrome (MDS) and acute myeloid leukemia
[66]. Mutant-p53 HSCs can trick their neighbors into thinking they are fitter. How cells compare
p53 levels remains a mystery. Soluble factors, cell–cell interactions and minerals could facilitate
the communication of p53 levels between HSCs. Moreover, mutations in p53 have been
shown to affect the secretome of cells to favor tumorigenesis, metastases, and immunoregu-
lation [67]. HSCs exist in a high-Ca2+ environment and must limit their intracellular Ca2+
to maintain proliferative capability [68]. The known fitness markers SPARC and Flower both
serve as Ca2+ channels and may consequently facilitate CC in the HSC niche [3]. Further studies
into the relationship between p53, SPARC/Flower, and Ca2+ in the bone marrow niche could illu-
minate how cells compare their p53 levels in this microenvironment and enact their competitive
mechanisms (Figure 2B).
A recent study demonstrated that low-grade inflammation provided a growth advantage to HSCs
with overactivated Toll-like receptor–tumor necrosis factor receptor-associated factor 6 (TRAF6),
a common cellular defect in MDS [69]. This mechanism hinged on the fact that TRAF6 HSCs
signaled through noncanonical NF-κB, while WT HSCs utilized the canonical pathway. This
study suggests that noncanonical NF-κB endows cells a growth advantage under inflammatory
conditions, but whether this depends on the presence of WT cells is not known and therefore
further studies are required.
Competition in the Thymus: Competition for Interleukin-7 (IL-7) Maintains a Healthy
Population of Thymocytes
Lymphoid progenitors undergo differentiation into mature, naïve T cells in the thymus [70] and are
constantly replenished from bone-marrow-derived precursors while also retaining self-renewal
capacity. CC mediates old thymocyte replacement and the disruption of this mechanism leads
to pathologies with genetic mutations and gene-expression profiles similar to those in T cell
acute lymphoblastic leukemia (T-ALL) [64]. In these experiments, WT thymus grafted on recipients
Figure 2. Examples of Cell Competition (CC) in Cancer Stem Cell (CSC) Selection and Immune Cell Development. (A) Hypothetical schematic diagram
illustrating the evolution of CSCs encountering competitive environments. The cells with red nuclei are depicted here as non-stem cancer cells and the cells without the
red nuclei are depicted as CSCs. The light blue cells in this diagram represent the original CSCs, which divide to give rise to daughter CSCs (light blue) and non-stem
cancer cells (light blue with red nuclei). Over time, the CSCs acquire mutations (and/or epigenetic changes). The CSCs with the 1st mutation (epigenetic change) are
the dark-blue cells; the CSCs with the 2nd, 3rd, 4th, and 5th mutations (and/or epigenetic changes, or a combination of both changes) are the light-purple, dark-
purple, black, and red cells, respectively. Consequently, over time, multiple mutant CSCs can exist in any given tumor. These CSCs compete with each other for
resources. Under stressful conditions such as chemotherapy or irradiation, the competition among the CSCs becomes more intense and only a few CSCs can win
because of mutations (and/or epigenetic changes) that give them a selective advantage under stressful situations. During the evolution of the tumor, the light-purple
and the dark-purple CSCs survive chemotherapy; however, only the black CSCs survive radiation. These CSCs can acquire another mutations (epigenetic changes)
(red CSC). In this way, the multiple competing CSCs evolve over time and accumulate additional mutations (and/or epigenetic changes) that provide a survival
advantage over other CSCs. This is a continuous process of clonal evolution that is amplified by selective pressures (hypoxia, chemotherapy, irradiation, nutrient
deprivation). (B) In the bone marrow, p53 mediates CC. Cells with lower p53 induce senescence of cells with higher p53. How hematopoietic stem cells (HSCs)
communicate and compare their levels of p53 remains unknown, but studies highlighting the inhibitory role of Ca2+ provide a solution. WT, wild type. (C) In the thymus,
thymocytes compete for interleukin-1 (IL-7), analogous to competition for Dpp in fly imaginal discs. Normally, long dwell times in the thymus reduce the efficiency with
which older thymocytes can utilize IL-7 and are replaced by younger thymocytes. However, when younger thymocytes (blue) cannot utilize IL-7 due to a genetic
deficiency, they are outcompeted by older thymocytes, and long dwell times in older thymocytes lead to genetic insult, which progresses to a T cell acute
lymphoblastic leukemia (T-ALL)-like phenotype. (D) Cancer cells can utilize most of the metabolic substrates in the tumor microenvironment (TME). Thus, the TME is a
nutrient-deprived, lactate-rich environment. This promotes the differentiation of immunosuppressive myeloid and lymphoid cells, which subsequently drives
carcinogenesis. (E) Lymphocytes must come into physical contact with dendritic cells to become activated. The mechanism for this competition is not known, nor is
the outcome of less-fit lymphocytes.
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tested whether bone marrow progenitors from recipient mice with different genetic backgrounds
could repopulate the thymus [64]. Signaling through IL-7, a hematopoietic growth factor, maintain
the expression of Bcl2, an antiapoptotic protein. Environmental IL-7 drove CC and conferred a
competitive advantage on progenitor cells with the ability to effectively utilize this factor [64]. Further
supporting this model, young bone marrow progenitors from IL-7ra−/- mice could not outcompete
older, WT thymocytes (Figure 2C) [64]. The response to cytokines ensures proper immune cell
development, homeostasis maintenance, and immunosurveillance for incipient cancer. However,
the ability to enact specific pro/anti-inflammatory pathways in response to cytokine signals also
depends on the ability of immune cells to meet their metabolic needs [71].
Competition in the TME: Metabolic Suppression of Innate and Adaptive Immune
Cells
Competition for nutrients drives carcinogenesis and the TME provides a set of ‘rules’ for immune
CC in the form of metabolic constraint [71]. Tumors that have metabolic winner phenotypes, like
those with Myc overexpression, regulate local immune cell interactions. Myc gain-of-function
mutations allow cancer cells to use a disproportionate amount of nutrients, which creates
a nutrient-depleted, hypoxic, and acidic environment due to the depletion of glucose and oxygen
and production of lactate [71,72]. Lactate has recently emerged as a pleiotropic immunoregulatory
molecule with many functions, including the promotion of M2macrophage gene expression through
lactylation of histones [73]. M2macrophages produce anti-inflammatory cytokines that promote the
differentiation of tumor-infiltrating lymphocytes towards a Treg phenotype, which promotes immuno-
suppression in the TME (Figure 2D) [73]. Future studies attempting to answer the question of nutrient
utilization and how subsequent changes in cell signaling affect fitnessmarker expression (i.e., Flower
isoform expression) in the TME will lead to the identification of druggable targets and pathways to
revert immunosuppression in the TME through novel CC mechanisms [74].
Competition in the Lymph Node: Mechanical CC Maintains an Efficacious Cell
Population
Mammals employ immune mechanisms to monitor cellular fitness and prevent disease [75]. In the
lymph node, T cells compete for space on dendritic cells for activation (Figure 2E) [76]. The mecha-
nisms regulating this process remain enigmatic, but the importance of mechanosensitive pathways
in T cell development and function is becoming increasingly recognized [77]. The Flower pathway
can mediate CC via surface contact between cells in Drosophila and human [3]. Although Flower
isoform expression has not been studied in human immune cells, selection through this pathway
presents an interestingmechanism bywhich apoptosis of less-fit naïve T cells can be induced during
education by lymph node dendritic cells. Education of the most competent naïve T cells promotes
the development of a robust immune response andmaintenance of immunosurveillance capabilities
to fend off infection and incipient cancers, respectively. The discovery of Flower isoformswith distinct
winner and loser potential in humans poses numerous questions about the complexity of
immune CC.While cytokines allow different subsets of immune cells to compete, fitness fingerprints
such as Flower isoforms could explain clonal CC.
Concluding Remarks
Studies have pointed towards the role of CC genes in cancer [4] and, as HIF-1α signaling under
hypoxic conditions promotes aggressiveness [6], understanding of the transcriptional regulation
of genes under hypoxia is highly relevant to understanding carcinogenesis in the context of CC.
Novel omics technologies will undoubtedly contribute to the growing list of genes involved in CC
(Table 1) and clarify their expression and role in other physiological and pathological conditions.
Studies have revealed how many of these genes could function as novel therapeutic targets,
regarding their tumor-promoting mechanisms or response to hypoxia [47,50–52]. It is also worth
Outstanding Questions
As new proteins involved in CC are dis-
covered, in what other ways do cells en-
gage in competition under homeostatic,
hypoxic, or malignant conditions?
As CC plays a role in ageing, can de-
fective CC explain other risk factors
for cancer at a molecular level?
What TME factors mediate CC in dif-
ferent tissue malignancies and how
does it differ between different cancers
and subtypes of cancers?
Does environmental oxygen play a role
in CC beyond inducing cell signaling
through HIFs? For example, does CC
mediate the susceptibility of cells to
reactive oxygen species?
What are the molecular details that
mediate CCpathways in immune cell de-
velopment, homeostasis, and function?
How do checkpoint blockade and
immunotherapy affect CC in the TME?
How can we modulate specific CC
pathways to enhance targeted anti-
cancer therapies and give healthy
cells an advantage over malignancy?
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noting that the selection of CSCs contributes to tumor heterogeneity and subsequently impairs
treatment efficacy, and selective modulation of CCmight provide a way to overcome this challenge
[8]. Last, a more complete understanding of the mechanisms regulating CC in immune cell popu-
lations and how these are influenced by pathological conditions could pave the way for novel
immunotherapeutic strategies (see Outstanding Questions).
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